Cargando…
Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial to improve quality of life: a study protocol for a randomized clinical trial
BACKGROUND: People living with chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) suffer impaired quality of life due to burdensome symptoms and depression. The Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial aims to d...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567600/ https://www.ncbi.nlm.nih.gov/pubmed/31196156 http://dx.doi.org/10.1186/s13063-019-3417-1 |
_version_ | 1783427113142976512 |
---|---|
author | Graney, Bridget A. Au, David H. Barón, Anna E. Cheng, Andrew Combs, Sara A. Glorioso, Thomas J. Paden, Grady Parsons, Elizabeth C. Rabin, Borsika A. Ritzwoller, Debra P. Stonecipher, Jessica-Jean Turvey, Carolyn Welsh, Carolyn H. Bekelman, David B. |
author_facet | Graney, Bridget A. Au, David H. Barón, Anna E. Cheng, Andrew Combs, Sara A. Glorioso, Thomas J. Paden, Grady Parsons, Elizabeth C. Rabin, Borsika A. Ritzwoller, Debra P. Stonecipher, Jessica-Jean Turvey, Carolyn Welsh, Carolyn H. Bekelman, David B. |
author_sort | Graney, Bridget A. |
collection | PubMed |
description | BACKGROUND: People living with chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) suffer impaired quality of life due to burdensome symptoms and depression. The Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial aims to determine the effect of a multidisciplinary, team-based intervention on quality of life in people with these common diseases. METHODS/DESIGN: The ADAPT trial is a two-site, patient-level randomized clinical trial that examines the effectiveness of the ADAPT intervention compared to usual care on patient-reported quality of life at 6 months in veterans with CHF, COPD or ILD with poor quality of life and increased risk for hospitalization or death. The ADAPT intervention involves a multidisciplinary team—a registered nurse, social worker, palliative care specialist, and primary care provider (with access to a pulmonologist and cardiologist)—who meet weekly to make recommendations and write orders for consideration by participants’ individual primary care providers. The nurse and social worker interact with participants over six visits to identify and manage a primary bothersome symptom and complete a structured psychosocial intervention and advance care planning. The primary outcome is change in patient-reported quality of life at 6 months as measured by the Functional Assessment of Chronic Illness Therapy-General questionnaire. Secondary outcomes at 6 months include change in symptom distress, depression, anxiety, disease-specific quality of life hospitalizations, and advance care planning communication and documentation. Intervention implementation will be assessed using a mixed-methods approach including a qualitative assessment of participants’ and intervention personnel experiences and a quantitative assessment of care delivery, resources, and cost. DISCUSSION: The ADAPT trial studies an innovative intervention designed to improve quality of life for veterans with common, burdensome illnesses by targeting key underlying factors—symptoms and depression—that impair quality of life but persist despite disease-specific therapies. Leveraging the skills of affiliate health providers with physician supervision will extend the reach of palliative care and improve quality of life for those with advanced disease within routine outpatient care. The hybrid effectiveness/implementation design of the ADAPT trial will shorten the time to broader dissemination if effective and create avenues for future research. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02713347. Registered March 19, 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3417-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6567600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65676002019-06-17 Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial to improve quality of life: a study protocol for a randomized clinical trial Graney, Bridget A. Au, David H. Barón, Anna E. Cheng, Andrew Combs, Sara A. Glorioso, Thomas J. Paden, Grady Parsons, Elizabeth C. Rabin, Borsika A. Ritzwoller, Debra P. Stonecipher, Jessica-Jean Turvey, Carolyn Welsh, Carolyn H. Bekelman, David B. Trials Study Protocol BACKGROUND: People living with chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) suffer impaired quality of life due to burdensome symptoms and depression. The Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial aims to determine the effect of a multidisciplinary, team-based intervention on quality of life in people with these common diseases. METHODS/DESIGN: The ADAPT trial is a two-site, patient-level randomized clinical trial that examines the effectiveness of the ADAPT intervention compared to usual care on patient-reported quality of life at 6 months in veterans with CHF, COPD or ILD with poor quality of life and increased risk for hospitalization or death. The ADAPT intervention involves a multidisciplinary team—a registered nurse, social worker, palliative care specialist, and primary care provider (with access to a pulmonologist and cardiologist)—who meet weekly to make recommendations and write orders for consideration by participants’ individual primary care providers. The nurse and social worker interact with participants over six visits to identify and manage a primary bothersome symptom and complete a structured psychosocial intervention and advance care planning. The primary outcome is change in patient-reported quality of life at 6 months as measured by the Functional Assessment of Chronic Illness Therapy-General questionnaire. Secondary outcomes at 6 months include change in symptom distress, depression, anxiety, disease-specific quality of life hospitalizations, and advance care planning communication and documentation. Intervention implementation will be assessed using a mixed-methods approach including a qualitative assessment of participants’ and intervention personnel experiences and a quantitative assessment of care delivery, resources, and cost. DISCUSSION: The ADAPT trial studies an innovative intervention designed to improve quality of life for veterans with common, burdensome illnesses by targeting key underlying factors—symptoms and depression—that impair quality of life but persist despite disease-specific therapies. Leveraging the skills of affiliate health providers with physician supervision will extend the reach of palliative care and improve quality of life for those with advanced disease within routine outpatient care. The hybrid effectiveness/implementation design of the ADAPT trial will shorten the time to broader dissemination if effective and create avenues for future research. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02713347. Registered March 19, 2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3417-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-13 /pmc/articles/PMC6567600/ /pubmed/31196156 http://dx.doi.org/10.1186/s13063-019-3417-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Graney, Bridget A. Au, David H. Barón, Anna E. Cheng, Andrew Combs, Sara A. Glorioso, Thomas J. Paden, Grady Parsons, Elizabeth C. Rabin, Borsika A. Ritzwoller, Debra P. Stonecipher, Jessica-Jean Turvey, Carolyn Welsh, Carolyn H. Bekelman, David B. Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial to improve quality of life: a study protocol for a randomized clinical trial |
title | Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial to improve quality of life: a study protocol for a randomized clinical trial |
title_full | Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial to improve quality of life: a study protocol for a randomized clinical trial |
title_fullStr | Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial to improve quality of life: a study protocol for a randomized clinical trial |
title_full_unstemmed | Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial to improve quality of life: a study protocol for a randomized clinical trial |
title_short | Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial to improve quality of life: a study protocol for a randomized clinical trial |
title_sort | advancing symptom alleviation with palliative treatment (adapt) trial to improve quality of life: a study protocol for a randomized clinical trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567600/ https://www.ncbi.nlm.nih.gov/pubmed/31196156 http://dx.doi.org/10.1186/s13063-019-3417-1 |
work_keys_str_mv | AT graneybridgeta advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT audavidh advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT baronannae advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT chengandrew advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT combssaraa advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT gloriosothomasj advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT padengrady advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT parsonselizabethc advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT rabinborsikaa advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT ritzwollerdebrap advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT stonecipherjessicajean advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT turveycarolyn advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT welshcarolynh advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial AT bekelmandavidb advancingsymptomalleviationwithpalliativetreatmentadapttrialtoimprovequalityoflifeastudyprotocolforarandomizedclinicaltrial |